Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Opsens Inc T.OPS

Healthcare Medical Devices
OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR... see more

Recent & Breaking News (TSX:OPS)

HAEMONETICS COMPLETES ACQUISITION OF OPSENS

Canada NewsWire December 12, 2023

OPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICS

Canada NewsWire December 8, 2023

OPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS

Canada NewsWire December 1, 2023

OPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED

Canada NewsWire November 28, 2023

OPSENS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS

Canada NewsWire November 22, 2023

INDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS SHAREHOLDERS VOTE "FOR" OPSENS INC. PLAN OF ARRANGEMENT WITH HAEMONETICS CORPORATION

Canada NewsWire November 13, 2023

OPSENS RECEIVES INTERIM ORDER AND FILES MANAGEMENT INFORMATION CIRCULAR IN CONNECTION WITH SPECIAL MEETING OF SHAREHOLDERS

Canada NewsWire November 2, 2023

OPSENS ANNOUNCES THE POSITIVE CLINICAL RESULTS FROM THE SAFE-TAVI STUDY WITH SAVVYWIRE IN EUROPE

Canada NewsWire October 23, 2023

OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in San Francisco October 23 - 26, 2023

Canada NewsWire October 17, 2023

OPSENS SIGNS DEFINITIVE AGREEMENT FOR ITS ACQUISITION BY HAEMONETICS

Canada NewsWire October 10, 2023

Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.

PR Newswire October 10, 2023

OPSENS ANNOUNCES A THIRD CONSECUTIVE QUARTER OF RECORD REVENUES FOR THIRD QUARTER FISCAL 2023

Canada NewsWire July 13, 2023

OPSENS TO HOST THIRD QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY JULY 13, 2023

Canada NewsWire July 6, 2023

OPSENS ANNOUNCES INCLUSION OF SAVVYWIRE(TM) IN COMPLETE TAVR STUDY

Canada NewsWire May 10, 2023

OpSens Announces Participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference

Newsfile April 20, 2023

OPSENS ANNOUNCES RECORD REVENUE FOR SECOND QUARTER FISCAL 2023

Canada NewsWire April 13, 2023

OPSENS ANNOUNCES COMPLETION OF ENROLLMENT IN SAFE-TAVI STUDY WITH SAVVYWIRE® IN EUROPE

Canada NewsWire April 11, 2023

OPSENS TO HOST SECOND QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY APRIL 13, 2023

Canada NewsWire April 6, 2023

OPSENS ANNOUNCES 1,000TH SAVVYWIRE PROCEDURE

Canada NewsWire April 5, 2023

OPSENS APPOINTS JOHN HANNIGAN AS CHIEF FINANCIAL OFFICER

Canada NewsWire March 27, 2023